PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

NCT06430736 · tracked via the Priya Life Science Switzerland tracker

Sponsor

Insel Gruppe AG, University Hospital Bern

Phase

Phase 2

Started

2024-07-01

Last updated

2024-07-08

Condition(s) studied

MyelomaLymphomaLeukemia

Investigational drug(s) / intervention(s)

Tocilizumab before CAR-T cell infusion →Tocilizumab at emerging CRS

Tocilizumab before CAR-T cell infusion: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells. Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm.

Tocilizumab at emerging CRS: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.

Study summary

Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients.

This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients planned to receive commercial CAR-T treatment for all registered indications comprising lymphomas, leukemias or myeloma at a single academic center (Bern Inselspital) * With written informed consent * Considered by the investigator to be clinically fit for this treatment * Patients aged ≥18 years Exclusion Criteria: * Previous Tocilizumab treatment within 3 months prior to CAR-T infusion * Patients with treatment with an investigational compound within 8 weeks prior to CAR-T infusion * Women who are pregnant or breast feeding, or women intending to become pregnant during the study period; or participants lacking safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases during study treatment and for a total of 12 months; Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Previous enrolment into the current study * Enrolment of the investigator, his/her family members, employees and other dependent persons

Primary outcome measure(s)

Incidence of CRS of all grades — 30 days
Number of patients with CRS of any grade according to the ASTCT (American Society for Transplantation and Cellular Therapy ) Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells ; including use of antipyretics

Trial sites (1)

Facility	City	Region	Status
Insel Gruppe AG	Bern	Canton of Bern	Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Safety & Feasibility of Ultrasound-assisted Non-invasive Measurement of Compressibility of the Thyroid Gland in Patients Scheduled for Surgical Removal Recruiting

Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease Recruiting

Night-to-Night Variability of Novel Physiological Parameters in Home Sleep Apnea Testing Recruiting

Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy Active, not recruiting

CT-guided Lung Biopsy Risk Optimization Method Recruiting

Other trials for the same condition

Breath Analysis for the Detection of Invasive Fungal Infections Recruiting

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0) Recruiting

Tumor Molecular Profiling in Early Phase Clinical Trials Recruiting

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06430736 on ClinicalTrials.gov ↗ ← All trials in Switzerland